About Voltage-gated delayed rectifier potassium channel KCNH1
Voltage-gated delayed rectifier potassium channel KCNH1 (KCNH1) is a protein
from Homo sapiens identified by UniProt accession
O95259, 989 residues long.
MolForge cross-references it against 0 known binders and
194 disease associations.
Target properties
| Protein name | Voltage-gated delayed rectifier potassium channel KCNH1 |
|---|
| UniProt accession | O95259 |
|---|
| Gene | KCNH1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 989 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (6)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (194)
Diseases linked to this target (Open Targets).
- Temple-Baraitser syndrome · score 0.78
- Zimmermann-Laband syndrome 1 · score 0.74
- multiple sclerosis · score 0.59
- Myasthenia gravis · score 0.57
- Intellectual disability · score 0.46
- Muscle weakness · score 0.46
- small cell carcinoma · score 0.46
- genetic disorder · score 0.45
- secondary progressive multiple sclerosis · score 0.43
- hematocrit · score 0.43
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O95259-F1 | alphafold | PREDICTED | 72.93 | — |
Amino-acid sequence (989 residues)
MTMAGGRRGL VAPQNTFLEN IVRRSNDTNF VLGNAQIVDW PIVYSNDGFC KLSGYHRAEV MQKSSTCSFM YGELTDKDTI EKVRQTFENY EMNSFEILMY KKNRTPVWFF VKIAPIRNEQ DKVVLFLCTF SDITAFKQPI EDDSCKGWGK FARLTRALTS SRGVLQQLAP SVQKGENVHK HSRLAEVLQL GSDILPQYKQ EAPKTPPHII LHYCVFKTTW DWIILILTFY TAILVPYNVS FKTRQNNVAW LVVDSIVDVI FLVDIVLNFH TTFVGPAGEV ISDPKLIRMN YLKTWFVIDL LSCLPYDVIN AFENVDEVSA FMGDPGKIGF ADQIPPPLEG RESQGISSLF SSLKVVRLLR LGRVARKLDH YIEYGAAVLV LLVCVFGLAA HWMACIWYSI GDYEIFDEDT KTIRNNSWLY QLAMDIGTPY QFNGSGSGKW EGGPSKNSVY ISSLYFTMTS LTSVGFGNIA PSTDIEKIFA VAIMMIGSLL YATIFGNVTT IFQQMYANTN RYHEMLNSVR DFLKLYQVPK GLSERVMDYI VSTWSMSRGI DTEKVLQICP KDMRADICVH LNRKVFKEHP AFRLASDGCL RALAMEFQTV HCAPGDLIYH AGESVDSLCF VVSGSLEVIQ DDEVVAILGK GDVFGDVFWK EATLAQSCAN VRALTYCDLH VIKRDALQKV LEFYTAFSHS FSRNLILTYN LRKRIVFRKI SDVKREEEER MKRKNEAPLI LPPDHPVRRL FQRFRQQKEA RLAAERGGRD LDDLDVEKGN VLTEHASANH SLVKASVVTV RESPATPVSF QAASTSGVPD HAKLQAPGSE CLGPKGGGGD CAKRKSWARF KDACGKSEDW NKVSKAESME TLPERTKASG EATLKKTDSC DSGITKSDLR LDNVGEARSP QDRSPILAEV KHSFYPIPEQ TLQATVLEVR HELKEDIKAL NAKMTNIEKQ LSEILRILTS RRSSQSPQEL FEISRPQSPE SERDIFGAS
Explore Voltage-gated delayed rectifier potassium channel KCNH1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets